TY - JOUR
T1 - Spacers and Valved Holding Chambers-The Risk of Switching to Different Chambers
AU - Scichilone, Nicola
AU - Dekhuijzen, Richard P.N.
AU - Levy, Mark
AU - Román-Rodriguez, Miguel
AU - Van Boven, Job F.M.
AU - Roche, Nicholas
AU - Dahl, Birthe Hellqvist
AU - Holmes, Stephen
AU - Van Boven, Job F.M.
AU - Conway, Joy
AU - Molimard, Mathieu
AU - Lavorini, Federico
AU - Usmani, Omar S.
AU - Barreto, Celeste
AU - Scullion, Jane
AU - Dekhuijzen, Richard P.N.
AU - Molimard, Mathieu
AU - Costello, Richard W.
AU - Conway, Joy
AU - Carroll, Will
PY - 2020
Y1 - 2020
N2 - Spacers are pressurized metered-dose inhaler (pMDI) accessory devices developed to reduce problems of poor inhaler technique with pMDIs. Spacers that feature a 1-way inspiratory valve are termed valved holding chambers (VHCs); they act as aerosol reservoirs, allowing the user to actuate the pMDI device and then inhale the medication in a 2-step process that helps users overcome challenges in coordinating pMDI actuation with inhalation. Both spacers and VHCs have been shown to increase fine particle delivery to the lungs, decrease oropharyngeal deposition, and reduce corticosteroid-related side effects such as throat irritation, dysphonia, and oral candidiasis commonly seen with the use of pMDIs alone. Spacers and VHCs are not all the same, and also are not interchangeable: the performance may vary according to their size, shape, material of manufacture and propensity to become electrostatically charged, their mode of interface with the patient, and the presence or otherwise of valves and feedback devices. Thus, pairing of a pMDI plus a spacer or a VHC should be considered as a unique delivery system. In this Rostrum we discuss the risk potential for a patient getting switched to a spacer or VHC that delivers a reduced dose medication.
AB - Spacers are pressurized metered-dose inhaler (pMDI) accessory devices developed to reduce problems of poor inhaler technique with pMDIs. Spacers that feature a 1-way inspiratory valve are termed valved holding chambers (VHCs); they act as aerosol reservoirs, allowing the user to actuate the pMDI device and then inhale the medication in a 2-step process that helps users overcome challenges in coordinating pMDI actuation with inhalation. Both spacers and VHCs have been shown to increase fine particle delivery to the lungs, decrease oropharyngeal deposition, and reduce corticosteroid-related side effects such as throat irritation, dysphonia, and oral candidiasis commonly seen with the use of pMDIs alone. Spacers and VHCs are not all the same, and also are not interchangeable: the performance may vary according to their size, shape, material of manufacture and propensity to become electrostatically charged, their mode of interface with the patient, and the presence or otherwise of valves and feedback devices. Thus, pairing of a pMDI plus a spacer or a VHC should be considered as a unique delivery system. In this Rostrum we discuss the risk potential for a patient getting switched to a spacer or VHC that delivers a reduced dose medication.
UR - http://hdl.handle.net/10447/412173
M3 - Article
SN - 2213-2201
JO - THE JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. IN PRACTICE
JF - THE JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. IN PRACTICE
ER -